Drug Trial Radar · NCT06639256
Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
258
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
May 26, 2027
Study completion Oct 26, 2027
Sponsor
- Lead sponsor
- Sichuan Huiyu Pharmaceutical Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, phase 1/2 study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of HY07121 in participants with advanced solid tumors.
Conditions
- Safety
- Tolerability
- Efficacy
Interventions
Test Product HY07121Drug
HY07121 should be administered intravenously at recommended dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation (Part One): Incidence and Nature of Dose-Limiting Toxicity (DLT)Time frame: 21 days during the first 3-week cycle
- Dose Escalation (Part One): Percentage of participants experiencing treatment-emergent adverse events (TEAEs)Time frame: Up to 2 years
- Dose Escalation (Part One): Percentage of participants experiencing Adverse Event (AE) related dose interruptions, dose delays, and dose intensityTime frame: Up to 2 years
- Dose Expansion (Part Two): Objective Response Rate (ORR)Time frame: Up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cancer Hospital of Shandong First Medical University
Jinan, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.